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Objective:We investigated whether a reduced iso-a acid derived from an extract of Humulus lupulus
L., META060, had an effect on weight gain, body composition, and metabolism in a high-fat–diet
(HFD) fed mouse model.
Methods:Weight gain was monitored for up to 20 wk in mice receiving a low-fat diet, an HFD, or an
HFD supplemented with META060 or rosiglitazone. Body composition was determined using dual-
energy x-ray absorptiometric analysis. Indirect calorimetric measurements were performed to
investigate the energy balance in the mice, and oral glucose tolerance tests were administered to
examine the effect of META060 on the glycemic response.
Results: The HFD-fed mice administered META060 for 14 wk had a signiﬁcantly lower mean weight
than HFD-fed mice (30.58  0.5 versus 37.88  0.7 g, P < 0.05). Indirect calorimetric measure-
ments showed an increased metabolic ﬂexibility in mice supplemented with META060. In addition,
glucose tolerance was improved, comparable to the effects of rosiglitazone treatment.
Conclusions: META060 has potential therapeutic value for managing obesity and insulin resistance,
and further research into the mechanism of action is warranted.
 2013 Elsevier Inc. All rights reserved.Introduction
The management of obesity has become a primary goal for
health care practitioners in response to the rising epidemic of
obesity-related chronic diseases, including type 2 diabetes mel-
litus and cardiovascular disease. Pharmaceutical approaches thatherlands Organization for
.) and the Dutch Diabetes




es, Institute of Metabolic
ll rights reserved.alter appetite, metabolism, or fat absorption include antide-
pressants, central nervous system stimulants, or peripherally
acting antiobesity drugs, and all have been associated with
adverse effects (reviewed by Kaplan [1]). Many people seek
natural therapies as an alternative to pharmaceuticals for weight
management. Yerba mate, yohimbe, aloe, pyruvate, St. John’s
wort, dandelion, and herbal diuretics have been used for weight
loss, although signiﬁcant clinical studies supporting their efﬁ-
cacy are lacking (reviewed by Pittler et al. [2]).
Iso-a acids derived from the hop plant (Humulus lupulus L.)
have been found to decrease plasma triacylglycerol and free fatty
acid (FA) levels in mice [3,4]. C57BL/6N mice fed a high-fat diet
(HFD) exhibited improved glucose tolerance after 14 d and
decreased insulin resistance after 10 d of administration of iso-a
acids. Furthermore, in a double-blinded, placebo-controlled pilot
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average 10.1% decrease in blood glucose levels and a 6.4%
decrease in glycated hemoglobin levels [4].
Iso-a acids are not particularly stable compounds, although
the reduced derivatives have been found to exhibit a greater
stability [5]. Furthermore, reduced iso-a acids have recently
shown a greater bioavailability than iso-a acids in humans [6].
Previous work in our laboratory to screen various botanical
extracts for lipogenic activity has resulted in the identiﬁcation
of a family of reduced iso-a acids [7]. One of the reduced iso-
a acids, META060, has exhibited anti-inﬂammatory activity
in vitro, mediated by the inhibition of the nuclear factor-kB
pathways [8,9]. Several reports have suggested a link between
obesity-induced inﬂammation and related metabolic disorders
such as insulin resistance (reviewed by Hummasti and Hota-
misligil [10] and Olefsky and Glass [11]). The objectives of the
present study were to determine the effects of META060
compared with rosiglitazone, a commonly used drug in the
treatment of type 2 diabetes mellitus, on body weight, energy
metabolism, glucose tolerance, and insulin sensitivity in
HFD-induced obese mice.
Materials and methods
Animals and dietary intervention
Wild-type C57Bl/6J male mice were purchased from Charles River (Maas-
tricht, The Netherlands). The mice were housed under standard conditions with
access towater and food ad libitum. For the 14-wk dietary intervention, the study
was startedwhen the animals were 19wk of age. Themicewere fed a low-fat diet
(LFD; 10% energy derived from lard fat; D12450, Research Diet Services, Wijk bij
Duurstede, The Netherlands), with a caloric content of 3.85 kcal/g, an HFD (45%
energy derived from lard fat; D12451, Research Diet Services), with a caloric
content of 4.73 kcal/g, or an HFD supplemented with META060 (100 mg ∙ kg1 ∙
d1) or rosiglitazone (1 mg ∙ kg1 ∙ d1; SmithKline Beecham Farma, Rijswijk,
The Netherlands). META060 was supplied by Hopsteiner, (St Paul, MN, USA) and
standards were purchased from ASBC (New York, NY, USA). The chemical
composition of META060 has been described previously [12]. META060 or rosi-
glitazone was added to the self-made HFD. Brieﬂy, rosiglitazone tablets (rosi-
glitazone maleate; Avandia, SmithKline Beecham Farma) or META060 powder
were crushed in a mortar with a pestle. Subsequently, the powder was mixed
with the 45% lard HFD powder diet (45% energy derived from lard fat; D12451,
Research Diet Services). For the HFD plus META060, 1.875 g of META060 per
kilogram of HFD powder was used. For rosiglitazone, 12 mg of powder was added
to 1 kg of HFD powder. The pellets were made by adding 2% agar (Sigma,
Zwijndrecht, Netherlands), freeze-dried to remove water, and stored at 20C. A
ﬁxed dosage was used throughout the dietary intervention. Based on previously
assessed food intake data, we knew that C57Bl/J6 mice on an HFD plus META060
(D12451, Research Diet Services) eat approximately 2.5 g of diet per day. Each
treatment group in the 14-wk intervention included 12 mice, and mice were
weighed weekly. The food intake was monitored weekly by weighing the food in
the cages manually. After 14 wk, animals in the LFD or HFD plus rosiglitazone
groups were sacriﬁced, after 4 h of fasting. Mice from the HFD group were
randomly divided into 2 groups: six were shifted to the HFD plus META060
(100 mg ∙ kg1 ∙ d1), and the remaining six mice continued receiving the HFD
for 6 wk. Likewise, mice supplemented with HFD plus META060 were divided
into two groups: six were shifted to the HFD, and the remaining six mice
continued receiving the HFD plus META060.
For the 5-wk dietary intervention, 12-wk-old mice were fed an HFD, an HFD
supplemented with META060 (100 mg ∙ kg1 ∙ d1), or an HFD supplemented
with rosiglitazone (1 mg ∙ kg1 ∙ d1). Each dietary group consisted of nine
animals. Body weight was measured weekly during the dietary intervention. All
experiments were approved by the animal ethics committee of the Leiden
University Medical Center.
Dual-energy x-ray absorptiometry
Animals were subjected to dual-energy x-ray absorptiometric (DEXA) analysis
after 4 h of fasting. The animals were weighed and sedated by a single intraperi-
toneal injection of a mixture of acepromazine (6.25 mg/kg; Neurotranq, Alfasan
International BV, Weesp, The Netherlands), midazolam (6.25 mg/kg; Dormicum,
Roche Diagnostics, Mijdrecht, The Netherlands), and fentanyl (0.31 mg/kg; Janssen
Pharmaceuticals, Tilburg, The Netherlands). The sedated animals were scanned intoto using a small-animal DEXA scanner (pDEXA, Norland Stratec Medizintechinik
GmbH, Birkenfeld, Germany) and the datawere analyzed by the software supplied
by the manufacturer. Fat mass and lean body mass were determined.
Indirect calorimetry
Groups of eight mice were subjected to individual indirect calorimetric
measurements for a period of 4 consecutive days using a Comprehensive Labo-
ratory Animal Monitoring System (Columbus Instruments, Columbus, OH, USA).
The cages were made of clear Plexiglas (30  10  9 cm, length by depth by
height). Before the start of the experiment, the animals were acclimated to the
cages and the single housing for a period of 24 h. The experimental analysis
started at 09:00 h and continued for 36 h. In the next 36 h of monitoring, the
animals were fasted overnight, and then food was replaced to assess the meta-
bolic ﬂexibility. The analyzed parameters included real-time food and water
intakes, meal size, frequency, and duration. Oxygen consumption (VO2) and
carbon dioxide production rates (VCO2) were measured at intervals of 7 min. The
respiratory exchange ratio (RER), a measurement for the metabolic substrate
choice, was calculated as the ratio of VCO2 to VO2. CHO and fat (FA) oxidation rates
were calculated using the following formulas [13]:
CHO ¼ 4:585 VCO2
 3:226 VO2
 4=1000
FA ¼ 1:695 VO2
 1:701 VCO2
 9=1000
The total energy expenditure was calculated from the sum of CHO and FA
oxidation. The activity was monitored as two-dimensional infrared beam breaks.
Fecal FA composition and concentration
Feces were collected over 4 d during week 4 of the 5-wk dietary intervention.
Feces were weighed, freeze-dried, and ground, and fecal FAs were subsequently
derivatized bymethyl esteriﬁcation. Therefore, 2mL ofmethanol/hexane (4:1 v/v)
containing 80 mg of penta-decanoic acid (C15:0) as an internal standard (Fluka,
Zwijndrecht, Netherlands) was added to 15 mg of feces. Then, 200 mL of acetyl
chloride (Merck,Darmstadt,Germany)wasadded, andthesampleswere incubated
at 95C. After subsequent cooling to 4C, 5 mL of 6% K2CO3 (Sigma) was added and
the sampleswere centrifuged (10min, 4000 rpm, 4C). Theupperhexane layerwas
isolated and used for gas chromatographic analysis of FA methyl esters. The FA
methyl esterswere separated on a 50-m 0.25-mmcapillarygas chromatographic
column (CP Sil 88, Agilent Technologies, Middelbrug, Netherlands) in a 3800 gas
chromatograph (Varian, Agilent Technologies,Middelburg,Netherlands) equipped
with a ﬂame ionization detector. The injector and ﬂame ionization detector were
kept at 270C. The column temperaturewasprogrammed from170C to 210C. The
FA methyl esters were introduced by split injection (split ratio 20:1). The quanti-
ﬁcation was based on the ratio of the area of the individual FA to the internal
standard.
Oral glucose tolerance test
Glucose and insulin levels were determined after overnight fasting during
week 5 of the 5-wk dietary intervention and after 14 wk of the 14-wk dietary
intervention. Blood was obtained by tail bleeding, and the glucose and insulin
concentrations were determined. Subsequently, the mice received an intragastric
load of D-glucose (2 g/kg) provided as a 20% solution in phosphate buffered saline.
Additional blood samples (30 mL) were collected by tail bleeding at 5, 15, 30, 60,
90, and 120 min after glucose loading for measurements of plasma insulin and
glucose concentrations. The glucose concentration was determined with
a glucose analyzer (Accu-Check, Sensor Comfort, Roche Diagnostics GmbH,
Germany) and the insulin concentration was determined by an immunoassay
(Chrystal Chem, Inc., Drovers Grove, IL, USA).
Statistical analysis
The data are presented as mean  standard error. Statistical differences were
calculated using the unpaired t test (SPSS 17, SPSS, Inc., Chicago, IL, USA) or two-
way analysis of variance with the Bonferroni post hoc test (GraphPad Prism, San
Diego, CA, USA). P < 0.05 was regarded as statistically signiﬁcant.
Results
Supplementation with META060 for 14 wk prevented
HFD-induced obesity
To determine the effect of META060 on HFD-induced obesity,
the mice were fed an LFD, an HFD, or an HFD supplemented
Fig. 1. META060 prevents HFD-induced obesity. (A) Mice were fed an LFD, an HFD, or an HFD supplemented with META060 100 mg ∙ kg1 ∙ d1 or Rosi 1 mg ∙ kg1 ∙ d1 for
14 wk. Mouse body weights were recorded every week (n ¼ 12 per group). ** P < 0.01, *** P < 0.001 HFD versus HFD þ META060; ^ P < 0.05, ^^ P < 0.01, ^^ ^ P < 0.001 HFD þ
META060 versus HFD þ Rosi; # P < 0.05, ## P < 0.01 HFD þMETA060 versus LFD. (B) After a 4-h fast, the lean body mass and fat mass were determined by dual-energy x-ray
absorptiometry (n ¼ 6 per group for HFD and META060, n ¼ 12 per group for Rosi). *** P < 0.001 HFD versus HFD þMETA060 and HFD versus HFD þ Rosi. (C) After the mice
were sacriﬁced, masses of gWAT and sWAT were determined (n ¼ 6 per group for HFD and META060, n ¼ 12 per group for Rosi). *** P < 0.001 HFD versus HFD þ META060
and HFD versus HFD þ Rosi. (D) At 14 wk, half the mice in the HFD group were shifted to HFD þMETA060 group, and half the mice in the HFD þMETA060 group were shifted
to the HFD-only group. Body weights were recorded weekly (n ¼ 6 per group). * P < 0.05, ** P < 0.01, *** P < 0.001 HFD versus HFD/ HFD þ META060; ^^ P < 0.01 HFD þ
META060 versus HFD þ META060/ HFD. Data are presented as mean  SE. gWAT, gonadal white adipose tissue; HFD, high-fat diet; LFD, low-fat diet; Rosi, rosiglitazone;
sWAT, subcutaneous white adipose tissue.
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kg1 ∙ d1 for 14 wk. Previous studies in a mouse model of
collagen-induced arthritis have reported an effect of META060
with 50mg ∙ kg1 ∙ d1 for decreasing cartilage degradation and
bone erosion, and doses up to 250 mg ∙ kg1 ∙ d1 were well
tolerated [8]. Therefore, a dose of 100 mg ∙ kg1 ∙ d1 was
selected for the present study investigating the effect of
META060 on body weight and metabolism in HFD-fed mice.
Rosiglitazone is an antidiabetic agent from the thiazolidinedione
class of drugs. Its mechanism of action is well known, involving
the activation of peroxisome proliferator-activated receptor-g,
and studies in HFD-fed mice have reported a decrease of insulin
levels with a dose of rosiglitazone 1 mg ∙ kg1 ∙ d1 [14]. The
mice receiving the HFD supplemented with META060 main-
tained similar body weights as those on the LFD over 14 wk and
body weights were signiﬁcantly lower in the HFD-fed mice at
week 3 and every subsequent time point up to week 14 (Fig. 1A).After 14 wk, the META060-supplemented mice weighed 19% less
than the HFD-fed control mice (30.58  0.5 versus 37.88  0.7 g,
P < 0.05) and were comparable in weight to mice fed the LFD for
14 wk (29.710.7 g). The mice supplemented with rosiglitazone
did not gain as much weight as those without supplementation,
although they gained signiﬁcantly more weight than the HFD/
META060- or LFD-fed mice (Fig. 1A). During the 14-wk dietary
intervention, no differences in food intake were observed.
To determine whether the decreased weight gain in the
META060-supplemented mice reﬂected a lower fat accumula-
tion compared with the HFD-only fed mice, the body composi-
tion of these mice was determined by DEXA analysis. The total
body fat of the mice supplemented with META060 was signiﬁ-
cantly lower than that of the HFD-fed mice (3.29  1.0 versus
12.121.1 g, P< 0.001; Fig.1B). At the end of the experiment, the
organs were dissected out and weighed. The META060 supple-
mentation decreased gonadal (1.17  0.2 versus 2.40  0.09 g,
Fig. 2. Comparison of 5-wk body weight increases in the 5-wk and 14-wk studies.
The mice were fed an HFD, an HFD supplemented with META060, or an HFD
supplemented with Rosi in two independent studies of different durations (5 or 14
wk). In the two studies, the mice were weighed at 5 wk. The mean body weight
difference from baseline  SE is represented for each group (n ¼ 9–12 per group). D,
difference; HFD, high-fat diet; Rosi, rosiglitazone.
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P < 0.001) white adipose tissue masses in the HFD-fed mice
compared with no-supplement controls (Fig. 1C).
At 15 wk, half the mice in the HFD group were shifted to the
HFD/META060 group, and half the mice in the HFD/META060
group were shifted to the HFD-only group. Body weight was
monitored weekly for 5 wk in these four treatment groups.
Although the animals maintained on the HFD for the entirety of
the experiment continued to gain weight, those shifted to the
HFD/META060 group lost a signiﬁcant amount of weight during
weeks 16 and 17, after which they began to gain weight again
(Fig. 1D). A concomitant decrease in food intake was observed in
the ﬁrst 2 wk after switching diets, followed by a rebound to
even higher levels than the food intake in mice in the HFD/
META060 group that did not switch diets (data not shown),
perhaps a reﬂection of an adjustment to the palatability differ-
ences between the distinct diets.META060 increased RER and metabolic ﬂexibility in mice fed an
HFD
To investigate how META060 protects against HFD-induced
obesity, an independent 5-wk study was initiated with three
treatment groups: HFD, HFD supplemented with META060
(100 mg ∙ kg1 ∙ d1), or HFD supplemented with rosiglitazone
(1 mg ∙ kg1 ∙ d1). In the ﬁrst 5 wk of the 14-wk intervention
study, the average weight gained in the HFD group was 5.61 
0.7 g, whereas the mice supplemented with META060 gained
0.68  0.3 g. In the 5-wk study, the average weight gained in the
HFD group was 2.58  0.4 g, and mice supplemented with
META060 gained 0.54  0.9 g (Fig. 2). Despite differences in the
absolute weight gained, which was likely due to the difference in
age of the mice at the start of each study, the META060
supplementation reproducibly decreased the relative HFD-
induced body weight gain in the two experiments.Whole-body substrate use was examined for approximately
36 h during week 4 of the dietary intervention. Four weeks of
dietary interventionwas chosen because, at this time point in the
14-wk study, body weight was still increasing and a new set
point had not yet been reached.
Although we did not directly compare the LFD group during
the 5-wk study, we knew from published and experimental data
that 5 wk of HFD feeding in mice results in an unaltered total
energy expenditure (kilocalories per hour) but in changes RER,
fat (FA), and CHO oxidation. Daytime RER was 0.84  0.04 versus
0.94  0.04, and night-time RER was 0.84  0.03 versus 0.93 
0.04 for the HFD versus LFD group, respectively (P < 0.05). The
daytime FA oxidationwas 0.17  0.05 versus 0.07  0.04, and the
night-time FA oxidation was 0.19  0.05 versus 0.08  0.06 for
the HFD versus LFD group, respectively (P < 0.05). The META060
or rosiglitazone intervention started from day 0, when the
animals were switched from chow to the HFD, as described in
MATERIALS AND METHODS.
The nocturnal and diurnal data were analyzed separately to
distinguish between periods of low (diurnal) and high
(nocturnal) physical activity. The total energy expenditure was
similar across all dietary intervention groups (Fig. 3A). For food
intake, no signiﬁcant differences were observed between the
groups (data not shown). Despite similarities in total energy
expenditure and food intake, the HFD-fed mice supplemented
with META060 or rosiglitazone exhibited a signiﬁcantly lower
mean nocturnal FA oxidation rate than the HFD-only group
(0.16  0.01 and 0.18  0.01 versus 0.22  0.01 kcal/h, P < 0.001
and P < 0.01, respectively), and rosiglitazone had a lower mean
diurnal FA oxidation rate compared with the control group
(0.12  0.01 versus 0.15  0.01 kcal/h, P < 0.05; Fig. 3B). In
addition, the nocturnal CHO oxidation levels were increased in
the HFD-fed mice that received META060 or rosiglitazone
compared with controls (0.36  0.02 and 0.35  0.01 versus
0.31  0.01 kcal/h, P < 0.01; Fig. 3C). This increased CHO-to-fat
oxidation ratio was reﬂected in the RER. META060 and rosigli-
tazone signiﬁcantly increased the RER in HFD-fed mice during
the diurnal period compared with the HFD-only–fed mice
(0.88  0.00 and 0.89  0.01 versus 0.86  0.01, P < 0.05 and P <
0.01, respectively) and during the nocturnal period (0.87  0.01
and 0.86  0.00 versus 0.83  0.01, P < 0.001, respectively;
Fig. 4A, B). To test the ability of the animals to adjust the fuel
oxidation to fuel availability (metabolic ﬂexibility), the animals
were fasted overnight; subsequently, the food was replaced and
the RER was monitored. The META060- and rosiglitazone-
supplemented mice had a signiﬁcantly higher RER when the
food was replaced compared with the HFD-only–treated mice
(0.94  0.00 and 0.94  0.00 versus 0.92  0.00, P < 0.001),
indicating greater metabolic ﬂexibility in the META060- or
rosiglitazone-fed animals (Fig. 4C). Physical activity measure-
ments did not show differences in either treatment group
compared with the HFD-only–fed mice (data not shown).
META060 had no effect on fecal FA composition and
concentration
Because META060 decreased fat oxidation, we investigated
whether fat absorption was impaired in the META060-
supplemented mice. The fecal FA composition and concentra-
tion were determined in samples collected during metabolic
cage experiments (data not shown). No difference was found in
total fecal weight. Furthermore, the quantitative gas chro-
matographic analysis showed equal fecal FA composition and
fecal FA content in all treatment groups. Together with the
Fig. 4. META060 increases RER and metabolic ﬂexibility. (A) The RER was moni-
tored for 36 h in HFD-fed mice without supplementation or supplemented with
META060 100 mg ∙ kg1 ∙ d1 or Rosi 1 mg ∙ kg1 ∙ d1. (B) The RER for the day or
night phase was calculated for each treatment group (n ¼ 8 per group). * P < 0.05, **
P < 0.01, *** P < 0.001. (C) The HFD-fed mice with or without supplementation with
META060 or Rosi for 4 wk were fasted overnight and then feeding was resumed.
The RER was calculated after fasting and after refeeding (n ¼ 8 per group). * P <
0.05. Data are presented as mean  SE. F, after fasting; HFD, high-fat diet; R, after




Fig. 3. META060 affects substrate use. During week 4 of the dietary intervention,
oxygen consumption and carbon dioxide production were recorded for 36 h in
HFD-fed mice without supplementation or supplemented with META060 100 mg ∙
kg1 ∙ d1 or Rosi 1 mg ∙ kg1 ∙ d1. The night period is represented by the shaded
area on the graph. (A) EE was calculated as described in MATERIALS AND METHODS. (B) FA
and (C) CHO oxidations for the day or night phase were calculated for the HFD-fed
mice without supplementation or in those supplemented with META060 or Rosi.
Data are presented as mean  SE (n ¼ 8 per group). * P < 0.05, ** P < 0.01, *** P <
0.001. CHO, carbohydrate; EE, energy expenditure; FA, fatty acid; HFD, high-fat diet;
Rosi, rosiglitazone.
I. O. C. M. Vroegrijk et al. / Nutrition 29 (2013) 276–283280equivalent food intake, this implies a similar intestinal absorp-
tion of lipids.
META060 improved glucose tolerance in HFD-fed mice
Because an increased CHO-to-fat oxidation ratio and an
increased metabolic ﬂexibility suggest protection against HFD-
induced insulin resistance, oral glucose tolerance tests were
performed during week 5 of the dietary intervention. After an
overnight fast, blood glucose concentrations were lower in
META060-supplementedmice comparedwith HFD-only–treated
mice (4.66  0.2 versus 5.34  0.3, P < 0.05; Fig. 5A), whereasfasting insulin levels were not signiﬁcantly different among
treatment groups (Fig. 5D). After the glucose challenge, plasma
glucose and insulin levels were determined at intervals up to 120
min, and areas under the curve (AUCs) were calculated. Glucose
concentrations were signiﬁcantly decreased for mice supple-
mented with META060 compared with HFD-fed mice at 15, 30,
90, and 120 min after the glucose challenge, and the mean AUC
was 20% lower than in HFD-fed mice (P < 0.05; Fig. 5B, C).
Rosiglitazone also signiﬁcantly decreased the plasma glucose
levels at 5, 30, 60, and 90min after the glucose challenge, and the
mean AUC was 15% lower than in HFD-fed mice (P < 0.05). These
observations show that META060 and rosiglitazone improved
glucose tolerance inmice fed an HFD for 5 wk. This may be due to




Fig. 5. META060 improves glucose tolerance. The mice were fed an HFD or an HFD supplemented with META060 100 mg ∙ kg1 ∙ d1 or Rosi 1 mg ∙ kg1 ∙ d1. During week
5 of the dietary intervention and after an overnight fast, the blood samples were collected, and (A) glucose and (D) insulin concentrations were determined. Oral glucose
tolerance tests were performed in fasted mice. (B) Glucose and (E) insulin concentrations were recorded at time points up to 120 min and AUCs for (C) glucose and (F) insulin
were calculated. Values are presented as mean  SE (n ¼ 7–9 per group). * P < 0.05 HFD versus HFD þMETA060,^P < 0.05 HFD versus HFD þ Rosi. AUC, area under the curve;
HFD, high-fat diet; Rosi, rosiglitazone.
I. O. C. M. Vroegrijk et al. / Nutrition 29 (2013) 276–283 281load because the time course and AUC for plasma insulin levels
were comparable in all groups (Fig. 5E, F).
After 14 wk of the dietary intervention, the fasting blood
glucose concentration in the META060-supplemented mice was
signiﬁcantly lower than in the HFD-fed mice (4.5  0.3 versus
5.9 0.3 mmol/L, P< 0.05; Fig. 6A). Moreover, the fasting insulin
concentration was signiﬁcantly decreased in the META060-
supplemented mice compared with the HFD-fed mice (0.14 
0.05 versus 0.42  0.09 ng/mL, P < 0.001; Fig. 6C). This implies
that after long-term META060 supplementation, insulin sensi-
tivity in HFD-fedmicewas increased. Oral glucose tolerance tests
were performed in mice and the blood glucose and insulinconcentrations were recorded at several time points up to 120
min after the challenge. The AUC for glucose was similar among
all groups (Fig. 6B). However, the AUC for insulin was increased
in the HFD group, and only rosiglitazone supplementation had
a statistically signiﬁcant effect on decreasing the insulin
response compared with the HFD group (40%, P < 0.05; Fig. 6D).
Discussion
In the present study, we investigated the effects of META060
on HFD-induced obesity and insulin resistance. Supplementation
with META060 decreased the weight gain in the HFD-fed mice.
A B
DC
Fig. 6. Long-termMETA060 supplementation decreases plasma glucose and insulin concentrations. Fasting (A) plasma glucose and (C) insulin concentrationswere determined
in mice fed an LFD, an HFD, or an HFD supplemented with META060 100 mg ∙ kg1 ∙ d1 for 14 wk as described in MATERIALS AND METHODS. Oral glucose tolerance tests were
performed in fastedmice, and blood concentrations of glucose and insulinwere determined at time points up to 120min. The AUCs are presented for (B) glucose and (D) insulin.
Values are presented as mean  SE (n ¼ 5–6 per group). * P < 0.05, ** P < 0.01, *** P < 0.001. AUC, area under the curve; HFD, high-fat diet; LFD, low-fat diet; Rosi, rosiglitazone.
I. O. C. M. Vroegrijk et al. / Nutrition 29 (2013) 276–283282This effect was signiﬁcant after 3 wk and was sustained for up to
20 wk. Furthermore, when the META060 feeding was termi-
nated, the mice began to gainweight rapidly. META060 inhibited
the fat accumulation in HFD-fed mice as evidenced by a decrease
in adipose tissue mass in mice supplemented with META060
compared with the HFD-fed control mice. In addition, META060
improved glucose tolerance after 5 wk of supplementation.
Moreover, long-term META060 supplementation in HFD-fed
mice clearly decreased the fasting blood glucose and insulin
levels. These data suggest that META060 improves glucose
homeostasis similarly to rosiglitazone and prevents HFD-
induced obesity and insulin resistance.
Rosiglitazone, an antidiabetic drug from the class of thiazoli-
dinediones, increases insulin sensitivity through its action on the
peroxisome proliferator-activated receptor-g and has exhibited
anti-inﬂammatory activity through a mechanism involving
nuclear factor-kB [15,16]. Although the mechanistic target(s) of
META060has notbeen identiﬁed, previous studies have indicated
that META060 has potent inhibitory effects on several kinases
regulating the nuclear factor-kB pathway, including glycogen
synthase kinase-3 and phosphatidyl inositol-3 kinase [12]. In thisstudy, META060 showed effects on insulin sensitivity similar to
that of rosiglitazone, prompting us to speculate whether the
improvement of glucose tolerance in META060-treated mice is
mediated through a peroxisome proliferator-activated recep-
tor-g–dependent mechanism. However, rosiglitazone was not as
effective at preventing weight gain in HFD-fed mice as was
META060, suggesting an alternative or additional mechanism of
action for META060.
Results from the metabolic experiments indicated that
supplementation with META060 increased the RER, metabolic
ﬂexibility, and the CHO-to-fat oxidation ratio in HFD-fed mice.
These observations are congruent with the increased insulin
sensitivity and improved CHO handling induced by META060.
Differences in metabolism and weight also were observed when
the fat intake or absorption was not consistent across treatment
groups. However, the metabolic experiments also indicated that
META060 did not affect total energy expenditure, food intake, or
FA secretion into the feces and thus do not explain the decrease in
weight gain of META060-supplemented mice. Therefore, meta-
bolic measurements may not be sufﬁcient to resolve a mecha-
nism for the global effects ofMETA060 on themousemetabolism.
I. O. C. M. Vroegrijk et al. / Nutrition 29 (2013) 276–283 283The mice used in the 5-wk study were slightly younger than
those in the longer-term experiment, and age may have
a potential impact on physical activity, food intake, energy
expenditure, or other metabolic processes. Although mice of
different ages may have distinct metabolic characteristics
contributing to the results we observed, the effects of META060
on weight gain and glucose homeostasis were consistent in the
short-term and long-term experiments.
Results from in vitro studies in a human cecal cell line have
shown that META060 increases Glucagon-like-peptide-1 (GPL-1)
secretion (data not shown). Because GLP-1 is an insulin-
sensitizing hormone, this in vitro effect of META060 is con-
sistent with the in vivo effects on glucose homeostasis. The
activation of GPR120, a G-protein–coupled receptor that regu-
lates GLP-1 secretion [17–19], may function as a mechanistic
target for META060-dependent GLP-1 secretion, although fur-
ther studies will be required to investigate this possibility.
Future studies will focus on elucidating the mechanism of
action underlying the effects of META060 on preventing weight
gain in HFD-fed mice and investigating whether META060 is
effective in decreasing weight in obese animals. META060
decreases fasting plasma glucose and insulin concentrations, and
further research into its activity on insulin signaling and hepa-
tocyte metabolism is needed. The present data suggest that
META060 may have therapeutic value as an antidiabetic or
antiobesity agent, and future investigations will evaluate its
potential clinical use.Conclusion
META060 supplementation signiﬁcantly decreased the
amount of weight gained in mice on an HFD. Indirect calori-
metric measurements showed an increased metabolic ﬂexibility
in mice, and the mice exhibited an improved glucose tolerance
comparable to the effects of rosiglitazone treatment. We
conclude that META060 has potential therapeutic value for
managing obesity and insulin resistance.Acknowledgments
The authors thank A. C. M. Pronk and J. Bos for excellent
technical assistance and Dr. Ingrid Fricks for assistance with the
manuscript preparation.References
[1] Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin North
Am 2010;39:69–79.
[2] Pittler MH, Schmidt K, Ernst E. Adverse events of herbal food supplements
for body weight reduction: systematic review. Obes Rev 2005;6:93–111.
[3] Shimura M, Hasumi A, Minato T, Hosono M, Miura Y, Mizutani S, et al.
Isohumulones modulate blood lipid status through the activation of PPAR
alpha. Biochim Biophys Acta 2005;1736:51–60.
[4] Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, et al. Iso-
humulones, bitter acids derived from hops, activate both peroxisome
proliferator-activated receptor alpha and gamma and reduce insulin
resistance. J Biol Chem 2004;279:33456–62.
[5] Intelmann D, Hofmann T. On the autoxidation of bitter-tasting iso-alpha-
acids in beer. J Agric Food Chem 2010;58:5059–67.
[6] Cattoor K, Remon JP, Boussery K, Van Bocxlaer J, Bracke M, De Keukeleire D,
et al. Bioavailability of hop-derived iso-alpha-acids and reduced deriva-
tives. Food Funct 2011;2:412–22.
[7] Babish JG, Pacioretty LM, Bland JS, Minich DM, Hu J, Tripp ML. Antidiabetic
screening of commercial botanical products in 3T3-L1 adipocytes and db/
db mice. J Med Food 2010;13:535–47.
[8] Konda VR, Desai A, Darland G, Bland JS, Tripp ML. META060 inhibits
osteoclastogenesis and MMPs in vitro, and reduces bone and cartilage
degradation in a mouse model of rheumatoid arthritis. Arthritis Rheum
2010;62:1683–92.
[9] Tripp M, Darland G, Lerman R, Lukaczer D, Bland J, Babish J. Hop and
modiﬁed hop extracts have potent in vitro anti-inﬂammatory properties.
Acta Horticulturae 2005;668:217–28.
[10] Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inﬂam-
mation in obesity and diabetes. Circ Res 2010;107:579–91.
[11] Olefsky JM, Glass CK. Macrophages, inﬂammation, and insulin resistance.
Annu Rev Physiol 2010;72:219–46.
[12] Desai A, Konda VR, Darland G, Austin M, Prabhu KS, Bland JS, et al.
META060 inhibits multiple kinases in the NF-kB pathway and suppresses
LPS-mediated inﬂammation in vitro and ex vivo. Inﬂamm Res 2009;58:
229–34.
[13] Peronnet F, Massicotte D. Table of nonprotein respiratory quotient: an
update. Can J Sport Sci 1991;16:23–9.
[14] Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, Xie M, et al. Adipose mito-
chondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and
improved by rosiglitazone. Diabetes 2007;56:1751–60.
[15] Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM,
Kliewer SA. An antidiabetic thiazolidinedione is a high afﬁnity ligand for
peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol
Chem 1995;270:12953–6.
[16] Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel
therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial
inﬂammatory response. J Clin Invest 1999;104:383–9.
[17] Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, et al. Free
fatty acids regulate gut incretin glucagon-like peptide-1 secretion through
GPR120. Nat Med 2005;11:90–4.
[18] Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is
an omega-3 fatty acid receptor mediating potent anti-inﬂammatory and
insulin-sensitizing effects. Cell 2010;142:687–98.
[19] Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-
sensing GPCRs ameliorates insulin resistance and inﬂammatory diseases.
Trends Pharmacol Sci 2011;32:543–50.
